Therapeutic Effects of DPP-4 Inhibitors In Diabetic Patients With COVID-19
The SARS-CoV-2 virus enters the cells by binding to Dipeptidyl peptidase-4. The dipeptidyl peptidase-4 (DPP-4) inhibitors have shown benefits in decreasing the mortality and severity associated with SARS–CoV-2 infection. DPP-4 has the potential to block the host CD26 receptor and modulate the DPP4/CD26 activity consequently restricting SARS–CoV-2 from entering the T cells. DPP-4 inhibitors including Gliptins, sDPP4 (soluble form), and AntiDPP4 vaccine is extensively used for